{
  "title": "Amendment to Duties Addressing the Synthetic Opioid Supply Chain in the People's Republic of China \u2013 The White House\n",
  "og:locale": "en_US",
  "og:type": "article",
  "og:title": "Amendment to Duties Addressing the Synthetic Opioid Supply Chain in the People's Republic of China",
  "og:description": "By the authority vested in me as President by the Constitution and the laws of the United\u00a0States of America, including the International Emergency",
  "og:url": "https://www.whitehouse.gov/presidential-actions/2025/02/amendment-to-duties-addressing-the-synthetic-opioid-supply-chain-in-the-peoples-republic-of-china/",
  "og:site_name": "The White House",
  "article:publisher": "https://www.facebook.com/WhiteHouse/",
  "article:published_time": "2025-02-05T16:52:56+00:00",
  "article:modified_time": "2025-02-07T17:44:03+00:00",
  "og:image": "https://www.whitehouse.gov/wp-content/uploads/2025/01/WH47-Social-Share-Card-Navy-1200x628-1.png",
  "og:image:width": "1200",
  "og:image:height": "628",
  "og:image:type": "image/png",
  "markdown": "[Presidential Actions](https://www.whitehouse.gov/presidential-actions/)\n\n# \t\t\t\t\t\u00a0AMENDMENT TO DUTIES ADDRESSING THE SYNTHETIC OPIOID SUPPLY CHAIN IN THE PEOPLE\u2019S REPUBLIC OF CHINA\t\t\t\t\n\nFebruary 5, 2025\n\n    By the authority vested in me as President by the Constitution and the laws of the United\u00a0States of America, including the International Emergency Economic Powers Act (50\u00a0U.S.C. 1701 *et seq*.), the National Emergencies Act (50\u00a0U.S.C. 1601 *et seq*.), section 604 of the Trade Act of 1974, as amended (19 U.S.C. 2483), and section\u00a0301 of\u00a0title\u00a03, United States Code, I hereby determine and order:\n\nSection 1. \u00a0Amendment. \u00a0Regarding the Executive Order of February 1, 2025 (Imposing Duties to Address the Synthetic Opioid Supply Chain in the People\u2019s Republic of China), the following shall replace subsection (g) of section 2:\u00a0\u00a0\u00a0\u00a0 \u201c(g)\u00a0 Duty-free *de minimis*treatment under 19 U.S.C. 1321 is available for otherwise eligible covered articles described in subsection (a) of this section, but shall cease to be available for such articles upon notification by the Secretary of Commerce to the President that adequate systems are in place to fully and expediently process and collect tariff revenue applicable pursuant to subsection (a) of this section for covered articles otherwise eligible for *de minimis*treatment.\u201d Sec. 2.\u00a0 General Provisions.\u00a0 (a) \u00a0Nothing in this order shall be construed to impair or otherwise affect:(i)\u00a0\u00a0 the authority granted by law to an executive department, agency, or the head thereof; or(ii)\u00a0 the functions of the Director of the Office of\u00a0Management and Budget relating to budgetary, administrative, or legislative proposals.(b)\u00a0 This order shall be implemented consistent with applicable law and subject to the availability of appropriations.\n\n(c) \u00a0This order is not intended to, and does not, create any right or benefit, substantive or procedural, enforceable at law or in equity by any party against the United\u00a0States, its departments, agencies, or entities, its officers, employees, or agents, or any other person.THE WHITE HOUSE,\u00a0\u00a0\u00a0 February 5, 2025.\n",
  "summary": "On February 5, 2025, a presidential amendment was issued regarding the duties related to the synthetic opioid supply chain in the People\u2019s Republic of China. This amendment modifies subsection (g) of section 2 from a previous executive order dated February 1, 2025, concerning the management of duties imposed on this supply chain. The amended order specifies that duty-free *de minimis* treatment under 19 U.S.C. 1321, applicable to certain covered articles, will no longer be available once the Secretary of Commerce notifies the President that appropriate systems are in place to process and collect the required tariffs effectively.\n\nThe document outlines the general provisions ensuring that the order does not interfere with existing legal authorities of executive departments or the function of the Office of Management and Budget. The order is subject to current laws and appropriations, and it clarifies that it does not establish any enforceable rights or benefits against the United States or its personnel for any entity or individual. This move reflects the administration's ongoing efforts to regulate the trade of synthetic opioids and their precursors more stringently, aiming to better monitor and manage importation and ensure proper taxation.\n",
  "eli5": "The President made a change to a rule about drugs coming from China. If some special conditions are met, the government will start collecting more money from these drugs. It's like setting up a rule to make sure the government gets its fair share when certain drugs are brought into the country.",
  "keywords": [
    "synthetic opioids",
    "China",
    "tariffs",
    "trade",
    "economic regulation",
    "de minimis",
    "U.S. Code"
  ],
  "issues": [
    "Clarification needed on what constitutes 'adequate systems' for tariff collection.",
    "Potential impact on trade relations with China."
  ],
  "citations": [
    "50 U.S.C. 1701 et seq.",
    "50 U.S.C. 1601 et seq.",
    "19 U.S.C. 2483",
    "19 U.S.C. 1321",
    "3 U.S.C. 301"
  ],
  "document_type": "Executive Order"
}